Johnson & Johnson (JNJ) announced that the FDA approved a combination therapy involving EFGR/MET inhibitor Rybrevant (amivantamab) for expanded use in certain patients with non-small cell lung cancer (NSCLC).With this nod, Rybrevant combined with standard-of-care chemotherapy (carboplatin and pemetrexed) is approved for treating patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions (ex19del) or L858R substitution mutations, whose disease has progressed on or after receiving with an ...

We invite our patients and their families to share their stories for a time capsule capturing the meaningful impact that the company’s innovative medicines and medtech solutions have had on their lifeOur global employee-led cycling event held from 13 to 15 September successfully raised funds for more than 1,000 impactful surgeries globally, bringing smiles to children in need through our support of Operation Smile SINGAPORE, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Johnson & Johnson (J&J), a leading healthcare co ...

Core Viewpoint - Disney stock (NYSE: DIS) is currently viewed as a better investment option compared to Johnson & Johnson stock (NYSE: JNJ) due to its attractive valuation and potential for growth despite recent performance challenges [1]. Group 1: Stock Performance Comparison - JNJ stock has gained 20% from $140 in early January 2021 to around $165, while DIS stock has declined 50% from $180 to $90 during the same period [2]. - Historical returns for JNJ were 11% in 2021, 6% in 2022, and -9% in 2023, whereas DIS returns were -15%, -44%, and 4% respectively [3]. Group 2: Revenue Growth Analysis - JNJ's adjusted revenue increased by 8% from $78.7 billion in 2021 to $85.2 billion in 2023, while Disney's sales rose 32% from $67.4 billion in fiscal 2021 to $88.9 billion in fiscal 2023 [4]. - JNJ's revenue growth was driven by pharmaceuticals and medical devices, with key products like Darzalex and Stelara contributing significantly [5]. - Disney's revenue growth was primarily fueled by its theme park business and a rebound in average spending post-COVID-19, although overall subscriber growth for its streaming services has slowed [6]. Group 3: Profitability Metrics - JNJ's operating margin improved from 26.6% in 2021 to 27.5% in 2023, while Disney's margin nearly doubled from 5.4% to 10.1% during the same period [8]. Group 4: Financial Risk Assessment - JNJ has a lower debt-to-equity ratio of 10% compared to Disney's 29%, and a higher cash-to-assets ratio of 14% versus Disney's 3%, indicating a stronger financial position for JNJ [9]. Group 5: Valuation Insights - JNJ's estimated valuation is $172 per share, slightly above its current market price of $166, trading at 17x forward expected earnings [10]. - Disney's estimated valuation is around $116 per share, approximately 30% above its current market price, trading at 18x forward expected adjusted earnings, suggesting significant growth potential [10].

Johnson & Johnson (JNJ) closed the most recent trading day at $166.99, moving +0.89% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 0.13%. On the other hand, the Dow registered a gain of 0.55%, and the technology-centric Nasdaq decreased by 0.52%.Coming into today, shares of the world's biggest maker of health care products had gained 3.85% in the past month. In that same time, the Medical sector gained 3.34%, while the S&P 500 gained 3.67%.Market partici ...

TAR-200 plus cetrelimab effective in reducing tumor size in those with muscle-invasive disease, potentially improving surgical outcomes and lowering risk of recurrenceBARCELONA, Spain, Sept. 16, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today interim data from the ongoing Phase 2 SunRISe-4 study showing neoadjuvant treatment with investigational TAR-200 plus cetrelimab (CET) achieved nearly double the pathological complete response (pCR) rate compared to CET alone in patients with muscle- ...

Clinical Trial Results - RYBREVANT® combined with chemotherapy (mFOLFOX6 or FOLFIRI) demonstrated promising antitumor activity in patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC) who had not previously received anti-EGFR therapy, with a median duration of response of 7.4 months and a median progression-free survival of 7.5 months [1] - The overall response rate (ORR) was 49%, with disease control observed in 88% of patients, and 21% of patients proceeded to curative-intent surgery due to strong antitumor activity [1] - The safety profile of RYBREVANT® plus chemotherapy was manageable, with no new safety signals observed, and the most frequent adverse events were neutropenia, rash, stomatitis, infusion-related reactions, and diarrhea [1] Study Design and Patient Population - OrigAMI-1 is an open-label Phase 1b/2 study assessing the efficacy and safety of RYBREVANT® plus mFOLFOX6 or FOLFIRI in anti-EGFR-naïve RAS/BRAF WT mCRC patients, with 43 patients treated in the study [2][3] - Patients were either in their first (26%) or second line (74%) of treatment for mCRC and had not been treated with specific anti-EGFR therapies [1] RYBREVANT® Overview - RYBREVANT® is a fully-human bispecific antibody targeting EGFR and MET, approved for the treatment of NSCLC with EGFR exon 20 insertion mutations in the U.S., Europe, and other markets [4] - It is also approved in combination with chemotherapy for first-line treatment of NSCLC with EGFR exon 20 insertion mutations and in combination with LAZCLUZE™ for NSCLC with EGFR exon 19 deletions or L858R substitution mutations [4][5] Regulatory Submissions and Approvals - Johnson & Johnson submitted a supplemental Biologics License Application (sBLA) to the U.S. FDA for RYBREVANT® in combination with chemotherapy for EGFR-mutated NSCLC patients who progressed on or after osimertinib, with this indication approved in Europe in August 2024 [5] - A BLA was submitted to the U.S. FDA for the subcutaneous formulation of RYBREVANT® in combination with LAZCLUZE™ for NSCLC indications, with a similar submission made to the EMA [6] Colorectal Cancer Background - Colorectal cancer is the third most common cancer globally, accounting for approximately 10% of all cancer cases and is the second leading cause of cancer-related deaths worldwide [8] - Left-sided colorectal cancer represents approximately 65% of cases, with around half of patients having mutations in the RAS genes, particularly KRAS, which influences treatment strategies [8] Ongoing Clinical Trials - RYBREVANT® is being studied in multiple clinical trials, including Phase 3 studies like MARIPOSA, MARIPOSA-2, PAPILLON, and PALOMA-3, evaluating its efficacy in various NSCLC settings [6][7] - Other trials include Phase 1/2 studies like METalmark, PolyDamas, and swalloWTail, exploring combination therapies and new formulations for NSCLC and other solid tumors [7]

Post-progression outcomes showed significant and sustained improvement for RYBREVANT® plus standard of care versus chemotherapy aloneBARCELONA, Sept. 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced updated results from the Phase 3 MARIPOSA-2 study which showed RYBREVANT® (amivantamab-vmjw) combined with chemotherapy led to consistent benefit across post-progression outcomes in adult patients with previously treated non-small cell lung cancer (NSCLC) with epidermal growth factor recepto ...

Johnson & Johnson (JNJ) announced that the FDA approved its blockbuster immunology medicine, Tremfya (guselkumab), for a third indication. The drug is approved to treat adults with moderately to severely active ulcerative colitis (UC).Tremfya is already approved for plaque psoriasis and active psoriatic arthritis (PsA) indications in several countries, including the United States and Europe.This latest approval is based on data from the phase IIb/III QUASAR study, which showed that a significantly greater p ...

On Tuesday, Johnson & Johnson JNJ announced results from the open-label Phase 2 SKIPPirr study, which evaluated additional prophylactic strategies to reduce the incidence of infusion-related reactions (IRRs) with intravenous (IV) Rybrevant (amivantamab-vmjw) in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations.The company, last month, agreed to acquire V-Wave for an upfront payment of $600 millio ...

Marks first EMA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and reduce levels of autoantibodies Filing based on the Phase 3 Vivacity-MG3 programme, the first registrational study results in the class demonstrating sustained disease control over 24 weeks in antibody-positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+ BEERSE, BELGIUM, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, ...